Moteur de recherche d’entreprises européennes
Financement de l’UE (6 183 822 €) : Améliorer la compréhension de l’immunité pulmonaire dans le contexte de la tuberculose afin d’établir un pipeline diversifié et innovant de vaccins contre la … Hor01/04/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Améliorer la compréhension de l’immunité pulmonaire dans le contexte de la tuberculose afin d’établir un pipeline diversifié et innovant de vaccins contre la tuberculose ciblant l’immunité des muqueuses
Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tuberculosis infection by novel vaccines would provide the most cost-effective approach to achieve the goals of the WHO End TB strategy and the Sustainable Development Goals of the United Nations. While there are few promising TB vaccine candidates available, innovation by new platforms and strategies is needed to ensure that the most effective and affordable vaccines are developed. TBVACHORIZON will innovate and diversify the global TB vaccine pipeline by pursuing four objectives: 1. Define the composition, spatial organisation and functioning of protective immune responses in the Mycobacterium tuberculosis-infected lung. 2. Evaluate whether mucosal re-vaccination with BCG and other live attenuated vaccines improves protective efficacy against tuberculosis infection in mice, non-human primates and humans. 3. Identify host immune response profiles and biomarkers of natural and vaccine-induced immune protection in the lung. 4. Support next generation TB vaccine development by standardised head-to-head testing of selected vaccine candidates in animals and the establishment of novel delivery systems, adjuvant formulations and GMP platforms for live attenuated vaccines. TBVACHORIZON will increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.
| Department of Health | ? |
| ACADEMISCH ZIEKENHUIS LEIDEN | 497 581 € |
| Centre National de la Recherche Scientifique CNRS | 949 991 € |
| CZ Vaccines SA | 500 000 € |
| Institut Pasteur | 497 500 € |
| Institut Pasteur de Lille Fondation | 491 000 € |
| Istituto Nazionale Per LE Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico | 350 250 € |
| Statens Serum Institut | 500 000 € |
| STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER | 900 000 € |
| STICHTING TUBERCULOSIS VACCINE INITIATIVE | 500 000 € |
| Universidad de Zaragoza | 500 000 € |
| UNIVERSITAET ULM | 497 500 € |
| Universite de Toulouse | 0,00 € |
https://cordis.europa.eu/project/id/101080309
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Department of Health, Leeds, Royaume Uni.
